10x Genomics, Inc. (TXG)
After hours:
| Previous Close | 27.80 |
| Open | 27.86 |
| Bid | 27.52 x 200 |
| Ask | 27.59 x 600 |
| Day's Range | 27.49 - 29.00 |
| 52 Week Range | 26.75 - 63.57 |
| Volume | |
| Avg. Volume | 1,403,338 |
| Market Cap | 3.287B |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.18 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.57 |
Zacks10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PR Newswire10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible fro
